Concepedia

Publication | Closed Access

Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer

DOI

13

Citations

22

References

2022

Year

S. Liddell, Sakti Chakrabarti, Grant Wintheiser, Tyler Zemla, Qian Shi, Sri Harsha Tella, Zhaohui Jin, Vanessa Wookey, Hind Hassan, Nguyen H. Tran,
JCO Precision Oncology

Abstract

ICIs are well tolerated and have modest antitumor activity in patients with advanced BTC. The study result supports the exploration of tumor mutational burden as a potential predictive biomarker for response to ICIs in patients with advanced BTC.

References

YearCitations

Page 1